Want to join the conversation?
$MYL lowered its 2016 adjusted EPS guidance to $4.70-4.90 from prior estimate of $4.85-5.15. The majority of this change in 2016 adjusted EPS guidance is result of changes in EpiPen Auto-Injector access programs and upcoming launch of generic to EpiPen Auto-Injector. $MYL remains committed to target of at least $6.00 in adjusted EPS in 2018.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.